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Summary: An assay for the estimation of guanosine deaminase is described. The method employs guanosine
äs Substrate and after incubation of serum and Substrate at 22 °C for 18 h the ammonia Hberated is estimated
using the Berthelot reaction. Absorbance is measured at 625 nm and the catalytic activity read from a Standard
curve obtained using ammonia Standards. The method provides reproducible measurement of serum guano-
sine deaminase. The results obtained using 'normal' sera have been used to calculate the 'normal ränge' for
the enzyme in serum. Preliminary results suggest that guanosine deaminase is increased in hepatitis and in
patients with liver metastases but normal in all other liver diseases including cirrhosis and obstructive jaun-
dice.
Bestimmung von Guanosindesaminase im Serum bei Lebererkrankungen
Zusammenfassung: Eine Methode zur Bestimmung von Guanosindesaminase wird beschrieben. Serum
wird mit Guanosin als Substrat inkubiert und nach 18 h bei 22 °C wird das freigesetzte Ammoniak mit der
/terfAefof-Reaktion bestimmt. Die Absorption wird bei 625 nm gemessen und die katalytische Aktivität aus
einer mit Ammoniak-Standards erstellten Standardkurve ermittelt. Die mit „NormaP'-Seren erhaltenen Er-
gebnisse wurden zur Berechnung des „Normale-Bereichs für das Enzym im Serum verwendet. Vorläufige
Ergebnisse weisen daraufhin, daß Guanosindesaminase bei Hepatitis und bei Patienten mit Lebermetastasen
erhöhtj bei allen anderen Erkrankungen der Leber, eingeschlossen Cirrhose und Verschlußikterus, jedoch
normal ist.
Introduction
The estimation of dCMP dieaminase (EC 3.5.4.12)
and cytidine deaminase (EC 3.5.4.5) in pregnancy
serum have become important parametefs in the
early detection of pre-eclamptic toxaemia (1), in-
trauterine death and viral hepatitis during pregnan-
cy. Both enzymes have been fpund to be within nor-
mal limits in essential hypertension (2).
The clinical value of estimating dCMP deaminase in
pregnancy serum has also been reported by Szekely
et al. (3).
During our investigation into the clinical usefulness
of estimating enzymes involved in DNA metabolism
durkig pregnancy it became increasingly clear that
dCMP deaminase and cytidine deaminase were also
increased in certain liver diseases. Furthermore the
activity of guanosine deaminase (EC 3.5.4.15) which
is an iriterconverting enzyme involved in DNA met-
abolism was increased in activity in liver diseases.
Guanosine deaminase was found to differ from
dCMP deaminase and cytidine deaminase in that it
was not raised in pre-eclamptic toxaemia or intraute-
rine death but was valuable in discriminating be-
tween certain groups of liver diseases. Normal serum
guanosine deaminase catalytic activity concentration
was found in alcoholic and cardiac cirrhosis, obstruc-
tive jaundice^ drug induced cholestatic jaundice and
acute cholecystitis with raised values in infective he-
patitis and in liver metastases. The enzyme therefore
provides a new means of differentiating liver dis-
eases. At present no test of liver function is capable
of discriminating between various liver disorders.
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However no method is available for the routine clini-
cal determination of serum guanosine deaminase ca-
talytic activity concentration. We have therefore
developed a new and sensitive method for the esti-
mation of guanosine deaminase in serum. With this
method the Substrate guanosine is converted to
xanthosine and ammonia. The ammonia liberated is
estimated using the Berthelot reaction without pro-
tein precipitation.
Materials and Methods
Reagen t s
The Substrate guanosine was purchased from Sigma Chemical Co.
All other reagents were purchased frorh British Drug Houses Ltd.
The phosphate buffer, pH 6.8; 0.15 mol/1 was prepared by the
addition of 53.4 ml of 0.15 mol/1 KH2PO4 to 46.6 ml of 0.15 mol/1
Na2HPO4. 80 mg of guanosine was suspended in 10 ml of distilled
water (28.2 mmol/1) and this stock solution was diluted l in 2 with
0.15 mol/1 phosphate buffer. Both Substrate Solutions were stable
for 48 hours at room temperature.
The phenol reagent was prepared by dissolving 10 g of phenol and
50 mg sodium nitroprusside in l l of distilled water. For the hy-
pochlorite reagent 5 g sodium hydroxide and 21.3 g disodium hy-
drogen orthophosphate were dissolved in approximately 800 ml
of distilled water to which was added 14 ml of a 100—140 g/l
solution of sodium hypochlorite and the volume made up to l 1.
Both the phenol and the hypochlorite Solutions were stable for
one week at 22 °C.
The stock ammonia Standard contained 7.13 mmol/1 of mmoni-
um sulphate. Working Standards were prepared by diluting the
stock Standard l in 10 with distilled water. Aliquots of 0.25, 0.5,
0.75 and 1.0 ml of this solution were further diluted to l ml with
water and 0. l ml taken for analysis. These Standards correspond
to 330, 660. 990 and 1320 mU/1 of enzyme catalytic activity con-
centration (cf. Procedure).
To construct the calibration curve the absorbance of the serum
blank was deducted from the absorbance of each Standard. The
Standards were equivalent to 330, 660, 990 and 1320 mU/l of eri-
zyme activity. One unit of enzyme catalytic activity concentration
(U/l) was defined s μιηοΐ of ammonia produced at 22 °C per min-
ute per Ihre of serum.
The highest working Standard (1320 mU/1) contained 1426 μιηοΐ/l
of NHJ. The tubes were incubated for 18 hours (1080 min) and
therefore the quantity of ammonia produced in μπιοί per minute
per Ihre would be:
1426
1080
1.320 U/l, corresponding to 1320 mU/1.
The enzyme catalytic activity concentrations of the test sera were
obtained by deducting the absorbance of the serum blank from
that of the test and reading the enzyme catalytic activity concen-
tration from the calibration chart.
The 4 hour technique at 37 °C would be performed exaetly s de-
scribed above for 22 °C.
Optimization of the assay
The Optimum conditions for the assay were determined using a
pooled serum and varying one constituent while keeping all other'
const ht.
Other enzyme assays
Alanine ammotransferase (37 °C) and γ-gl tafnyl tfansferase
(37 °C) were assayed using the Boehfinger Mannheim Diagnostic
kits (Cat. No. 124954). The Technicon Instruments, SMA tech-
nique (method no. SF4-006FG5) was used for estimatifig the ca^
talytic activity concentration of serum lkaline phosphatase
(37 °C). Cytidine deaminase (22 0C) was assayed aecording to
Jones et al. (4).
Samples
All blood samples were obtained from venous puncture allowed
to clot and the serum removed and either assayed immediately or
stored at -20 °C.
Procedure
To two tubes was pipetted 0.1 ml of serum and to one of the tubes
was added 0.15 ml of substfate and to the second tube 0.15 ml of
buffer. Both tubes were then capped and incubated in a water
bath for 18 h at 22 °C. At the end of this time 1.5 ml of phenol
reagent was added, mixed and 1.5 ml of hypochlorite solution
added. The tubes were then incubated at 37 °C for 30 min and the
blue colour read at 625 nm.
Standards for the calibration curve were prepared by the addition
ofO.l ml of the respective Standards, 0.15 ml of buffer and 0. i ml
of a single serum sample, incubated at 22 °C for 18 h and subse-
quent treatment was s for the tests.
The ammonia content of the single serum used in all four Stand-
ards for construction of the calibration curve was estimated by the
addition of 0.15 ml of buffer to 0.1 ml of serum.
Results
pH-optimum
To determine the optim m pH for the assay, phos*
phate buffer ranging in pH from 5.5 to 8.0 at 0.5 pH
intervals were used. The Optimum pH for enzyme
activity was 6.8 and therefore in the final procedure
a pH of 6.8 was utilized. Fig re l ill strates the re.·
sults obtained.
Substrate
Varying concentrations of guanosine were used
ranging from 0.7 mmol/1 to 17.6 mmol/1. The Opti-
mum Substrate concentration was fou&d to be be-
tween 10 atid 18 mmol/1 s ill strated in figure 2. A
concentration of 14.12 mmol/1 was used throughout
this work, since this gaye a convenient quantity (40
mg) of Substrate for weighing. '
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Fig. 1. Optimum pH for serum guanosine deaminase activity. Fig. 2. Optimum Substrate concentration for serum guanosine
deaminase.
Linearity
The upper limit of enzyme activity at which a linear
response could be evoked was determined using di-
lutions of a human serum from a patient possessing a
very high level of enzyme catalytic activity concen-
tration who was suffering from infective hepatitis.
The value for this serum was 2300 mU/L The serum
was diluted with a serum containing normal catalytic
concentration of guanosine deaminase (300 mU/1).
Dilutions could not be made with buffer because of
the quenching effect of serum protein on the Berthe-
lot colour reaction. Figure 3 ill strates the results ob^
tained and it is apparent that the technique described
was linear up to 2300 mU/1 of enzyme catalytic ac-
tivity concentration.
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Fig. 3. Linearity of the methpd described for the estimation of
serum guanosine deaminase at 22 °C. Values found when
serum of high cataiytic activity concentration (2300 mUA)
was diluted with a serum of normal catalytic activity con-
centration (300 mU/lj.
Linearity of the method with time
The serym with 2300 mU/1 of guanosine deaminase
was estimated at two hourly intervals over a period
of 18 h. A linear response was obtained throughout
this period.
Influence of serum on the Berthelot reaction
Pooled serum was added to the Standards since se-
rum had a quenching effect upon the colour reaction.
Varying vol mes of phenol and hypochlorite rea-
gents were added to 0.1 ml of serum in the presence
of the highest working Standard (= 1320 mU/1) and
maximum colour development was obtained by the
addition of 1.5 ml of phenol and hypochlorite solu-
tions. A dialyzed ammoiiia free serum was used to
investigate the quenching effect of protein. Varying
the concentrations of the dialyzed serum between 40
g/l and 100 g/1 had iio effect upon the colour reac-
tion when 1.5 ml of phenol and hypochlorite solu-
tions were added. The addition of phenol and hy-
pochlorite Solutions in vol mes below 1.0 ml de-
creased the absorbance. Althqugh serum protein
quenches the colour reaction the quenching is con-
stant between a serum protein concentration of 40
g/l and 100 g/l. It is therefore for this reason that a
single serum was added to the Standards. A similar
technique has been described by Jones et al. (4).
Reproducibility
When 20 replicates from a pooled human serum
were placed within batches of samples and analysed
on twenty consecutive days the mean value obtained
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was 840 mU/1 and the Standard Variation was 16
mU/1. Day to day reproducibility was maintained by
estimating the activity of aliquots of a pooled serum
stored at -20°C.
'Reference ränge'
The sera from 100 'normal' patients were assayed to
find a mean and 'reference ränge'. Gare was taken in
the selection of the sera to ensure that the patients
did not have a disease. All of these sera were ob-
tained from clinically healthy people attending the
staff health department prior to employment äs hos^
pital staff. The mean, Standard deviation and refer-
ence ränge for 18 h at 22 °C and 4 h at 37 °C are
listed in table 1. The reference ränge was 'nofmally'
distributed.
Tab. 1. Determination of mean and reference ranges of serum
guanosine deaminase catalytic activity concentration.
Number of determinations
Mean guanosine deaminase values
(mU/1)
Standard deviation (SD)
(mU/1)
Reference ränge (± 2x SD)
(mU/1)
Incubation
1 8 hours
at22°C
100
220
80
60-380
4 hours
at 37 °C
100
600
250
100-1100
Serum guanosine deaminase in liver disorders
The serum guanosine deaminase catalytic activity
concentrations among the various groups of patients
are compared in figure 4. The catalytic concentration
was increased markedly in hepatitis and in liver met-
astases. It did not change significantly in other liver
disorders such äs cirrhosis and obstructive jaundice.
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Fig. 4. Serum guano.sine diesaminase catalytic activity concentra-
tions in various liver disorders. The line shows the normal
ränge.
Cornparison of guanosine deaminase with other tests
of liver function
Of the enzymes investigated -glutamyltransferäse
was the most sensitive indicäitdr of liver disease gen-
erally with 46 öf the 51 sera tested having increased
activity followed by alkaline phosphatase with 35 se-
fa and alanine aminotransferase with 28.
In infective hepatitis and liver metastases guanosine
deaminase was increased in all 21 patients (fig. 4),
alkaline phosphatase in 18, -glutamyltransferase in
16 and alanine aminotransferase in 15. Figure 5 il-
lüstrates the results obtained for alanine aminötfäns-
ferase and guanosine deaminase in a patient recover-
ing from infective hepatitis.
Stability of guanosine deaminase activity
No detectable loss of enzyme activity was found
when sera were stored at -20 °C for 14 days, while
storage at 4°C caused approximately a 10% loss of
total activity in 3 days. Wherever possible fresh se-
rum was used for routine measurement.
Discussion ,.
Guanosine deaminase is distinct from guanine deam-
inase (EC 3.5.4.15) which has no action on guano-
sine, adenosine öf adenine (5, 6). Furthermore, gua-
nine deaminase is found in liveY and kidney (7).
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Fig. 5. Typical results found for serum cytidine deaminase
(O O), guanosine deaminase (x x) and alanine ami-
notransferase ( —— ) catalytic activity concentrations in
a patient with infective Hepatitis.
Guanine deaminase activity on the other band has
not been found in sefüm ffom patients suffering
from kidney diseases (8).
This is the first report describing the clinical useful-
ness of estimating the serum activity of guanosine
deaminase in liver disease.
Our preliminary findings suggest that serum guano-
sine deaminase catalytic activity concentration is in^
creased in viral hepatitis and in patients with liver
metastases but not in alcoholic cirrhosis, cardiac cir-
rhosis or obstructive jaundice. On the other band,
alanine aminötransferase, Y^glutamyltransferase and
alkaliiie phosphatase were freqüently increased in
these diseases.
Serum cytidine deaminase catalytic activity concen-
tration has been found by üs to be increased in viräl
hepatitis büt the estimation of guanosine deaminase
has the advantage in that white blood cells contain a
high aetivity of cytidine deaminase with no detecta-
ble guanosine deaminase actfvlty.
The technique described for the estimation of guan-
osine deaminase is simple and inexpensive but re-
quires an 18 h incubation period, although the 4 h
technique at 37 °C described by us (9) for the esti-
mation of cytidine deaminase can equally be applied
to the estimation of guanosine deaminase in situa-
tions where an extremely urgent result is required.
This 4 h technique utilizes the NADH-glutamate de-
hydrogenase reaction.
The technique described entails incubations at 22 °C
for 18 h or 37 °C for 4 h. It was found impractical to
use a temperature at 30 °C since at this temperature
an incubation period of approximately 8 h would be
required. An 8 h incubation period would not be
suitable for use during the working day. In situations
where the ambient laboratory temperatures are diffi-
cult to maintain at 22 °C then the 4 h at 37 °C would
be the most suitable to use.
In the 4 h technique a temperature of 37 °C is used
to obtain maximurn ammonia production. The total
time to complete this method would be approxi-
mately 6 h and would be unsuitable for use in a nor-
mal working day.
An incubation at 37 °C for 18 h would result in ex-
cess production of ammonia which would in turn
cause non-linearity with poor reproducibility of re-
sults. Furthermore, at 37 °C bacterial growth could
become a problem. Therefore an 18 h incubation at
22 °C äs described by Ressler (10) for dCMP deami-
nase estimation was preferred.
The 18 h incubation at 22 °C has not in our expe-
rience caused problems in the growth of microorga-
nisms which could have caused increased ammonia
production. Although sterile glass tubes have been
used for blood collection and sterile polystyrene
reaction tubes used for the assays, aseptic precau-
tions have not been taken.
Since the technique gives a linear response over the
enzyine ränge 0—2300 mU/1 direct measurement
can be made over an extremely wide ränge. In our
experience no patient serum has given guanosine
deaminase values greater than 2450 mU/1.
Numerous enzymes have been proposed äs sensitive
iiidicators of liver disease but none have been found
by us to be so discriminating äs the deaminases. Fur-
thermore, guanosine deaminase reflects the severity
of the disease.
Measurement of the rate of production of ammonia
offers a simple means of detecting guanosine deami-
nase and is ideally suited for incorporation into a liv-
er function profile. A detailed clinical evaluation of
serum guanosine deaminase together with a multi-
centre evaluation of the enzyme is at present taking
place.
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